Equities Analysts Issue Forecasts for Spectrum Pharmaceuticals, Inc.’s Q1 2018 Earnings (SPPI)
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) – Analysts at Jefferies Group issued their Q1 2018 EPS estimates for Spectrum Pharmaceuticals in a report issued on Wednesday. Jefferies Group analyst M. Andrews forecasts that the biotechnology company will post earnings per share of ($0.35) for the quarter. Jefferies Group also issued estimates for Spectrum Pharmaceuticals’ Q2 2018 earnings at ($0.32) EPS, Q3 2018 earnings at ($0.33) EPS, Q4 2018 earnings at ($0.33) EPS, FY2018 earnings at ($1.32) EPS, FY2019 earnings at ($0.90) EPS, FY2020 earnings at ($0.18) EPS and FY2021 earnings at $1.03 EPS.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last posted its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.04). The firm had revenue of $28.57 million during the quarter, compared to the consensus estimate of $33.18 million. Spectrum Pharmaceuticals had a negative net margin of 70.66% and a negative return on equity of 30.68%. Spectrum Pharmaceuticals’s revenue was down 18.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.10) EPS.
Spectrum Pharmaceuticals (SPPI) opened at $18.67 on Friday. The stock has a market capitalization of $2,000.00, a PE ratio of -27.46 and a beta of 1.58. Spectrum Pharmaceuticals has a 1-year low of $5.47 and a 1-year high of $23.50.
A number of large investors have recently added to or reduced their stakes in SPPI. New York State Common Retirement Fund lifted its stake in Spectrum Pharmaceuticals by 19.4% in the second quarter. New York State Common Retirement Fund now owns 80,500 shares of the biotechnology company’s stock valued at $600,000 after buying an additional 13,099 shares during the period. Dimensional Fund Advisors LP lifted its stake in Spectrum Pharmaceuticals by 21.0% in the second quarter. Dimensional Fund Advisors LP now owns 2,674,679 shares of the biotechnology company’s stock valued at $19,926,000 after buying an additional 463,434 shares during the period. State Street Corp lifted its stake in Spectrum Pharmaceuticals by 28.3% in the second quarter. State Street Corp now owns 3,020,563 shares of the biotechnology company’s stock valued at $22,507,000 after buying an additional 666,605 shares during the period. Crossmark Global Holdings Inc. acquired a new position in Spectrum Pharmaceuticals in the third quarter valued at about $212,000. Finally, New York State Teachers Retirement System lifted its stake in Spectrum Pharmaceuticals by 4.6% in the third quarter. New York State Teachers Retirement System now owns 88,795 shares of the biotechnology company’s stock valued at $1,249,000 after buying an additional 3,900 shares during the period. 78.37% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/03/11/equities-analysts-issue-forecasts-for-spectrum-pharmaceuticals-inc-s-q1-2018-earnings-sppi.html.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.